InvestorsHub Logo
Followers 7
Posts 299
Boards Moderated 0
Alias Born 01/07/2010

Re: McMagyar post# 87662

Friday, 01/13/2017 8:55:58 PM

Friday, January 13, 2017 8:55:58 PM

Post# of 462427
McMag & Others, this is a productive discussion. To continue with your thought, why did Allergan pass us up for Heptares' small molecule agonists targeting muscarinic M1 and M4 receptors?

Why has Biogen passed us up to this date to partner with Rodin Therapeutics in Jan '16 for a HDAC2 inhibitor? Why did BIIB pass us up to this date to partner with AC Immune in April '16 for their anti-tau program?

These are all beyond beta-amyloid busters...

Same goes for Lilly, Janssen, etc, etc.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News